Hao Herui, Bao Fengjiao, Wang Yuru, Li Ning, Gong Yanhua
School of Disaster and Emergency Medicine, Tianjin University, No. 92 Weijin Road, Nankai District, Tianjin 300072, China; Faculty of Medicine, Tianjin University, China.
School of Disaster and Emergency Medicine, Tianjin University, No. 92 Weijin Road, Nankai District, Tianjin 300072, China; Faculty of Medicine, Tianjin University, China; Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin, China.
Drug Discov Today. 2025 Jun;30(6):104377. doi: 10.1016/j.drudis.2025.104377. Epub 2025 May 8.
Acute kidney injury (AKI) is a common fatal condition among hospitalized patients. AKI may be induced by a variety of complicating factors such as sepsis, ischemia-reperfusion injury, nephrotoxic substances, and rhabdomyolysis. At present, symptomatic treatment is mainly used, and there are no US Food and Drug Administration (FDA)-approved drugs for the prevention or treatment of AKI. Peptides have become a promising area of research in AKI treatment because of their high efficiency and low toxicity. In this paper, we systematically review the experimental advancements of peptide therapy for AKI, analyze the mechanism of peptide action in different pathological models, discuss the challenges facing peptide therapy, and provide a scientific basis for further clinical research.